PCaI joins with Cancer ABCs to advocate for protection of access to cancer and other drugs

For many years now, here in the USA, access to FDA-approved drugs for the treatment of cancer and other severe forms of disorder have been guaranteed under Medicare. … READ MORE …

Court invalidates patent on J&J’s Zytiga, but …

Here in the US, according to news reports issued late on Friday, a federal court in New Jersey invalidated the last remaining patent held by Johnson & Johnson on their formulation of abiraterone acetate, known as Zytiga, and used in the treatment of castration-resistant forms of prostate cancer. … READ MORE …

President Trump signs “right to try” legislation into law

The issue as to whether the new, so-called “right-to-try” legislation is a good idea or not is contentious and your sitemaster has no interest in getting into that discussion. What is a fact is that it has now been signed into law. … READ MORE …

Can Provenge come back from the moribund?

It wouldn’t be wise to expect anything big in a hurry, but it is now clear that the Sanpower Group, which acquired Dendreon about a year ago, has serious plans to do things that the “old Dendreon” never did to optimize the potential of sipuleucel-T (Provenge). … READ MORE …

Cancer care today in rural communities across America

Readers who are interested in a current assessment of issues affecting the quality of (and access to) prostate cancer care services for those living in rural communities across America may want to download and review the two articles listed below. … READ MORE …

Guessing the future price of the next major breakthrough in prostate cancer treatment

In an article published on Monday September 28, in Pharmaceutical Executive (a well-known biopharmaceutical industry trade journal) a senior health care public relations executive recently laid out a detailed rationale for why the industry needs to do a better job … READ MORE …

NHS to stop covering cost of cabazitaxel for mCRPC as of November

As reported in a wide spectrum of media over the past few days (see here for example), on Friday last week the National Health Service announced that it would no longer cover the costs associated with use of cabazitaxel (Jevtana) in the treatment of metastatic, castration-resistant prostate cancer (mCRPC) through the UK’s Cancer Drugs Fund — effective as of November 1, 2015. … READ MORE …